Literature DB >> 15923294

Comparison of non-invasive sampling methods for detection of HPV in rural African women.

N Lack1, B West, D Jeffries, G Ekpo, L Morison, W P Soutter, G Walraven, L Boryseiwicz.   

Abstract

BACKGROUND: The prevalence of cervical cancer is extremely high in low income countries, primarily because of a lack of cytological screening. The link between human papillomavirus (HPV) and cervical cancer has long been recognised, and it has been suggested that isolated HPV testing in women who do not participate in existing screening programmes may be used to identify women at higher risk of developing cervical cancer. This community based study compares two self administered techniques for detecting HPV (tampons and self administered swabs) with a clinician directed technique, the cervical cytobrush.
METHODS: 377 rural women were interviewed and of these 210 women had full gynaecological examination, and accepted all three sampling methods for HPV. HPV typing of DNA extracts was performed using polymerase chain reaction and enzyme linked immunosorbent assay techniques.
RESULTS: Using the cervical cytobrush as the gold standard, self administered swabs (SAS) showed a sensitivity of 63.9%, and tampons showed a sensitivity of 72.4%. The acceptability of these two tests was 97.1% and 84.6% respectively. When combining acceptability with sensitivity, the SAS detected 61.9% and the tampons detected 60.9% of the true positives.
CONCLUSION: In a setting where women are at a considerable risk of developing cervical cancer, with no access to a formal screening programme, self directed HPV testing could be a useful screening tool in identifying those women at increased risk who may require further investigation.

Entities:  

Mesh:

Year:  2005        PMID: 15923294      PMCID: PMC1744971          DOI: 10.1136/sti.2004.010413

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  11 in total

1.  The burden of reproductive-organ disease in rural women in The Gambia, West Africa.

Authors:  G Walraven; C Scherf; B West; G Ekpo; K Paine; R Coleman; R Bailey; L Morison
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

2.  Randomized clinical trial of PCR-determined human papillomavirus detection methods: self-sampling versus clinician-directed--biologic concordance and women's preferences.

Authors:  Diane M Harper; Walter W Noll; Dorothy R Belloni; Bernard F Cole
Journal:  Am J Obstet Gynecol       Date:  2002-03       Impact factor: 8.661

3.  Condylomata acuminata and human genital cancer.

Authors:  H zur Hausen
Journal:  Cancer Res       Date:  1976-02       Impact factor: 12.701

4.  A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings.

Authors:  M V Jacobs; P J Snijders; A J van den Brule; T J Helmerhorst; C J Meijer; J M Walboomers
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

5.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

6.  Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study.

Authors:  M A Nobbenhuis; J M Walboomers; T J Helmerhorst; L Rozendaal; A J Remmink; E K Risse; H C van der Linden; F J Voorhorst; P Kenemans; C J Meijer
Journal:  Lancet       Date:  1999-07-03       Impact factor: 79.321

7.  Estimates of the worldwide incidence of 25 major cancers in 1990.

Authors:  D M Parkin; P Pisani; J Ferlay
Journal:  Int J Cancer       Date:  1999-03-15       Impact factor: 7.396

8.  Management of women who test positive for high-risk types of human papillomavirus: the HART study.

Authors:  J Cuzick; A Szarewski; H Cubie; G Hulman; H Kitchener; D Luesley; E McGoogan; U Menon; G Terry; R Edwards; C Brooks; M Desai; C Gie; L Ho; I Jacobs; C Pickles; P Sasieni
Journal:  Lancet       Date:  2003-12-06       Impact factor: 79.321

9.  Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico.

Authors:  Jorge Salmerón; Eduardo Lazcano-Ponce; Attila Lorincz; Mauricio Hernández; Pilar Hernández; Ahideé Leyva; Mario Uribe; Horacio Manzanares; Alfredo Antunez; Enrique Carmona; Brigitte M Ronnett; Mark E Sherman; David Bishai; Daron Ferris; Yvonne Flores; Elsa Yunes; Keerti V Shah
Journal:  Cancer Causes Control       Date:  2003-08       Impact factor: 2.506

10.  Human papillomavirus testing in primary cervical screening.

Authors:  J Cuzick; A Szarewski; G Terry; L Ho; A Hanby; P Maddox; M Anderson; G Kocjan; S T Steele; J Guillebaud
Journal:  Lancet       Date:  1995-06-17       Impact factor: 79.321

View more
  21 in total

1.  Agreement between self- and clinician-collected specimen results for detection and typing of high-risk human papillomavirus in specimens from women in Gugulethu, South Africa.

Authors:  Heidi E Jones; Bruce R Allan; Janneke H H M van de Wijgert; Lydia Altini; Sylvia M Taylor; Alana de Kock; Nicol Coetzee; Anna-Lise Williamson
Journal:  J Clin Microbiol       Date:  2007-04-04       Impact factor: 5.948

2.  Dry storage and transport of a cervicovaginal self-sample by use of the Evalyn Brush, providing reliable human papillomavirus detection combined with comfort for women.

Authors:  Romy van Baars; Remko P Bosgraaf; Bram W A ter Harmsel; Willem J G Melchers; Wim G V Quint; Ruud L M Bekkers
Journal:  J Clin Microbiol       Date:  2012-09-26       Impact factor: 5.948

3.  A Viable and Simple Self-Sampling Method for Human Papillomavirus Detection among South African Adolescents.

Authors:  David H Adler; Fatima Laher; Erica Lazarus; Katherine Grzesik; Glenda E Gray; Bruce Allan; Anna-Lise Williamson
Journal:  J Immunol Tech Infect Dis       Date:  2013-09-18

4.  High level of agreement between clinician-collected and self-collected samples for HPV detection among South African adolescents.

Authors:  D H Adler; A Almudevar; G E Gray; B Allan; A-L Williamson
Journal:  J Pediatr Adolesc Gynecol       Date:  2012-08       Impact factor: 1.814

5.  Human papillomavirus genotypes associated with cervical cytologic abnormalities and HIV infection in Ugandan women.

Authors:  D B Blossom; R H Beigi; J J Farrell; W Mackay; B Qadadri; D R Brown; S Rwambuya; C J Walker; F S Kambugu; F W Abdul-Karim; C C Whalen; R A Salata
Journal:  J Med Virol       Date:  2007-06       Impact factor: 2.327

6.  High Rate of β-Globin DNA Detection Validates Self-Sampling in Herpes Simplex Virus Shedding Studies.

Authors:  Andrew Mujugira; Meei-Li Huang; Stacy Selke; Linda Drolette; Amalia S Magaret; Anna Wald
Journal:  Sex Transm Dis       Date:  2015-12       Impact factor: 2.830

7.  Prevalence and predictors of high-risk human papillomavirus infection in a population-based sample of women in rural Uganda.

Authors:  Stephen Asiimwe; Christopher C Whalen; Daniel J Tisch; Elioda Tumwesigye; Ajay K Sethi
Journal:  Int J STD AIDS       Date:  2008-09       Impact factor: 1.359

8.  Determinants of incidence and clearance of high-risk human papillomavirus infections in rural Rakai, Uganda.

Authors:  Mahboobeh Safaeian; Mohammad Kiddugavu; Patti E Gravitt; Stephen J Gange; Joseph Ssekasanvu; Dan Murokora; Marc Sklar; David Serwadda; Maria J Wawer; Keerti V Shah; Ron Gray
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-06       Impact factor: 4.254

9.  HPV self-sampling for cervical cancer screening: a systematic review of values and preferences.

Authors:  Holly Nishimura; Ping Teresa Yeh; Habibat Oguntade; Caitlin E Kennedy; Manjulaa Narasimhan
Journal:  BMJ Glob Health       Date:  2021-05

10.  HPV infection in women with and without cervical cancer in Conakry, Guinea.

Authors:  N Keita; G M Clifford; M Koulibaly; K Douno; I Kabba; M Haba; B S Sylla; F J van Kemenade; P J F Snijders; C J L M Meijer; S Franceschi
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.